0001493152-15-000181.txt : 20150115 0001493152-15-000181.hdr.sgml : 20150115 20150115160021 ACCESSION NUMBER: 0001493152-15-000181 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150115 DATE AS OF CHANGE: 20150115 EFFECTIVENESS DATE: 20150115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Imprimis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001360214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450567010 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-232341 FILM NUMBER: 15530026 BUSINESS ADDRESS: STREET 1: 12264 EL CAMINO REAL STREET 2: SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-704-4042 MAIL ADDRESS: STREET 1: 12264 EL CAMINO REAL STREET 2: SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC DATE OF NAME CHANGE: 20070912 FORMER COMPANY: FORMER CONFORMED NAME: Bywater Resources, Inc DATE OF NAME CHANGE: 20060421 D 1 primary_doc.xml X0707 D LIVE 0001360214 Imprimis Pharmaceuticals, Inc. 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA CALIFORNIA 92130 858-704-4040 DELAWARE Bywater Resources, Inc. Transdel Pharmaceuticals, Inc. TRANSDEL PHARMACEUTICALS INC Bywater Resources, Inc Corporation true Mark L. Baum 12264 El Camino Real Suite 350 San Diego CA CALIFORNIA 92130 Executive Officer Director Andrew R. Boll 12264 El Camino Real Suite 350 San Diego CA CALIFORNIA 92130 Executive Officer Stephen G. Austin 12264 El Camino Real Suite 350 San Diego CA CALIFORNIA 92130 Director Richard L. Lindstrom 12264 El Camino Real Suite 350 San Diego CA CALIFORNIA 92130 Director Robert J. Kammer 12264 El Camino Real Suite 350 San Diego CA CALIFORNIA 92130 Director William H. Nelson 12264 El Camino Real Suite 350 San Diego CA CALIFORNIA 92130 Director Pharmaceuticals Decline to Disclose 06b false 2015-01-01 true true true true Issuer acquired South Coast Specialty Compounding, Inc. ("Park") and paid a portion of the closing purchase price, and may pay a portion of the deferred purchase price, at the sellers' election, in Issuer's equity. 0 818750 500000 318750 A portion of the consideration paid at the closing of the acquisition of Park was paid in Issuer's equity and a portion of the deferred compensation may, at the sellers' election, be paid in Issuer's equity or in cash. false 2 0 0 0 false Imprimis Pharmaceuticals, Inc. /s/ Andrew R. Boll Andrew R. Boll Vice President, Accounting and Public Reporting 2015-01-15